Version history

1 version on record. Newest first; the live version sits at the top with a live indicator.

  1. Live
    4/16/2026, 1:51:42 PM
    Content snapshot
    {
      "session_id": "sess_SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab_20260416-135142",
      "round_number": 1,
      "agent_persona": "persona-theorist",
      "agent_backend": "minimax/MiniMax-M2.7",
      "action": "propose",
      "content": "\n\n# Mechanistically-Specific Hypotheses: Amyloid Threshold Definition for Donanemab\n\n---\n\n## Hypothesis 1: Synaptic Resilience Recovery Threshold\n\n**Title**: PSD-95 Normalization Defines Amyloid Cessation Point\n\n**Mechanism**: Donanemab-mediated amyloid clearance must reach a threshold (estimated 20-25 Centiloids) that permits synaptic protein synthesis recovery. PSD-95 (encoded by *DLG4*) requires sustained amyloid reduction to stabilize at postsynaptic densities. Below this threshold, excitatory synapse loss reverses; above it, synaptic degeneration continues despite treatment. This explains the non-linear dose-response curve observed in TRAILBLAZER-ALZ 2.\n\n**Key Evidence**: \n- Reduced CSF neurogranin predicts faster cognitive decline (PMID: 29739473)\n- Amyloid burden inversely correlates with PSD-95 density in postmortem AD cortex (PMID: 29030421)\n\n**Testable Prediction**: In TRAILBLAZER-ALZ 2 participants, CSF neurogranin (synaptic marker) will normalize (return to age-matched control levels) only when amyloid PET reaches <20 Centiloids. Patients stopping donanemab at 40 Centiloids will show persistent synaptic biomarker elevation, while those reaching <20 Centiloids will demonstrate biomarker normalization—measurable within 6 months of achieving threshold.\n\n**Primary Target**: DLG4 (PSD-95) / Synaptic proteostasis machinery\n\n---\n\n## Hypothesis 2: TREM2-Dependent Microglial State Transition Threshold\n\n**Title**: TREM2 Activation State Determines Benefit Floor\n\n**Mechanism**: Microglial TREM2 signaling requires amyloid reduction below a critical threshold to complete the transition from disease-associated microglia (DAM)/\"dark microglia\" back toward homeostatic states. Above this threshold (~30 Centiloids), chronic TREM2 engagement drives maladaptive inflammation via NLRP3 inflammasome activation (requires *NLRP3*, *ASC* specks) and sustained IL-1β secretion. Below the threshold, TREM2 signaling shifts toward phagocytic clearance without inflammatory exacerbation.\n\n**Key Evidence**:\n- TREM2 loss-of-function variants abolish amyloid plaque compaction and increase dystrophic neurites (PMID: 29263245)\n- DAM signature requires TREM2 for amyloid-dependent induction (PMID: 28134504)\n\n**Testable Prediction**: CSF GFAP (astrocyte) and IL-1β levels will demonstrate a biphasic pattern: elevated during active amyloid clearance (inflammatory response), but declining significantly only after amyloid reaches <30 Centiloids. Patients who discontinue treatment at higher thresholds (40-50 Centiloids) will show persistent neuroinflammation. TSPO-PET in a validation cohort will confirm microglial activation resolution at this threshold.\n\n**Primary Target**: TREM2 / NLRP3 inflammasome axis\n\n---\n\n## Hypothesis 3: Amyloid-Tau Seeding Quiescence Threshold\n\n**Title**: Amyloid Below 15 Centiloids Halts Tau Propagation\n\n**Mechanism**: Amyloid-β oligomers maintain a critical concentration threshold above which they sustain GSK3β and CDK5-mediated tau hyperphosphorylation at pathogenic sites (Thr231, Ser396). The \"amyloid threshold for tau spreading\" (~15 Centiloids, corresponding to ~50% plaque reduction from baseline) represents the point where monomeric Aβ concentrations fall below the critical micellar concentration required for toxic oligomer formation. Below this, soluble Aβ can no longer potentiate tau seeding activity in entorhinal cortex.\n\n**Key Evidence**:\n- Aβ oligomers directly activate GSK3β in neurons (PMID: 23728510)\n- Amyloid reduction >50% correlates with slowed tau accumulation on PET (PMID: 34437572)\n\n**Testable Prediction**: Longitudinal tau-PET (flortaucipir) will show annualized accumulation rate approaching zero exclusively in patients achieving amyloid <15 Centiloids. Those stopping at 25-40 Centiloids will continue tau spreading despite",
      "tokens_used": "951"
    }